[HTML][HTML] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao… - … andrology and urology, 2015 - ncbi.nlm.nih.gov
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
[PDF][PDF] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao, CP Evans - 2015 - researchgate.net
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
[PDF][PDF] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao, CP Evans - 2015 - Citeseer
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
T Chandrasekar, JC Yang, AC Gao… - … Andrology and Urology, 2015 - europepmc.org
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
[HTML][HTML] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao… - … Andrology and Urology, 2015 - tau.amegroups.org
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
[引用][C] Mechanisms of resistance in castration‐resistant prostate cancer (CRPC)
T Chandrasekar - Transl Androl Urol, 2015 - cir.nii.ac.jp
Mechanisms of resistance in castration‐resistant prostate cancer (CRPC) | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[PDF][PDF] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao, CP Evans - 2015 - cdn.amegroups.cn
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao… - … Andrology and Urology, 2015 - escholarship.org
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang… - Translational …, 2015 - pubmed.ncbi.nlm.nih.gov
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
T Chandrasekar, JC Yang, AC Gao… - … Andrology and Urology, 2015 - europepmc.org
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …